Iodine Density Threshold to Distinguish Between Enhancing and Nonenhancing Renal Lesions With Dual-Layer Dual-Energy...

This study aimed to determine the optimal threshold iodine density to distinguish enhancing and nonenhancing renal masses with dual-layer dual-energy CT (dlDECT).

In this retrospective, HIPAA-compliant, institutional review board-approved study, 383 consecutive renal mass dlDECT studies from September 5, 2018, through December 15, 2022, were reviewed for enhancing solid renal masses with ≥∆20 HU. Studies with simple cysts in the same interval served as controls. Lesion ROI HU measurements on unenhanced and nephrographic phases and ROI iodine density measurements of each lesion and the abdominal aorta for normalization were recorded. The mean lesion HU values and absolute and normalized iodine densities were compared with enhancing and nonenhancing renal lesions using a two-sample t test. The diagnostic accuracy of iodine thresholds was assessed by calculating sensitivity and specificity, with receiver operating characteristic curve and AUC analysis.

There were 38 enhancing and 39 nonenhancing renal lesions. The mean (standard deviation [SD]) ∆HU was 73.5 (38.7) and 3.9 (5.1) HU for enhancing and nonenhancing lesions, respectively. The mean absolute iodine density was significantly different for enhancing and nonenhancing lesions (3.2 [1.7] mg/mL and 0.20 [0.22] mg/mL, respectively; P < 0.0001). Normalized mean iodine density was significantly different for enhancing and nonenhancing lesions (0.62 [0.33] mg/mL and 0.04 [0.04] mg/mL, respectively; P < 0.0001). The optimal absolute iodine density threshold of 0.70 mg/mL (AUC, 0.999) and normalized iodine density threshold of 0.11 mg/mL (AUC, 0.999) were 100% sensitive and 97.4% specific for discriminating enhancing and nonenhancing renal lesions.

This study provides absolute and normalized iodine density thresholds to distinguish enhancing and nonenhancing renal lesions with high sensitivity and specificity using dlDECT.